TFOS European Ambassador meeting: Unmet needs and future scientific and clinical solutions for ocular surface diseases

Erickson, Susan; Sullivan, Amy Gallant; Barabino, Stefano; Begovic, Enesa; Benítez-del-Castillo, J.M.; Bombardieri, Stefano; Borges, José Salgado; Brzheskiy, V.V.; Bulat, Nina; Cerim, Alma; Craig, Jennifer P.; Cușnir, Valeriu; Doan, Serge; Dulger, Erol; Farrant, Sarah; Geerling, Gerd; Goldblum, David; Голубев, С. Ю.; Gomes, José Álvaro Pereira; González-Meijóme, José Manuel; Grupcheva, Christina; Gündüz, Ömür Uçakhan; Horwath‐Winter, Jutta; Kallmark, Fredrik; Karanadze, N A; Karcic, Huda Hajjir; Karcic, Suvad; Kontadakis, Georgios A.; Messmer, Elisabeth M.; Mrugacz, Małgorzata; Murphy, Conor C; O'Leary, Olivia; Procopciuc, Vitalie; Pult, Heiko; P, Raus; Şahin, Afsun; Setälä, Niko; Stănilă, Adriana; Stănilă, Dan; Utheim, Tor Paaske; Vehof, Jelle; Versura, Piera; Willcox, Mark; Wolffsohn, James S.; Zagórski, Z; Zoëga, Gunnar Már; Sullivan, David A.

doi:10.1016/j.jtos.2020.05.006

Cited by 11 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As Tear Film & Ocular Surface Society's DE Workshop II (TFOS DEWS II) Epidemiology Report was published in 2017 (Stapleton et al 2017), there has been a growing interest in collecting data on the prevalence and risk factors of DE in different countries. However, in most of the countries, including Finland, updated epidemiologic data on DE are still lacking (Erickson et al 2020). In addition, the available estimates of DE vary markedly ranging from 5% to 50% due to varying diagnostic criteria and sample characteristics, such as age, sex and ethnicity (Stapleton et al 2017).…”

Section: Discussionmentioning

confidence: 99%

Ocular surface health of the Finnish elderly population

Aapola

Nättinen

Suurkuukka

et al. 2022

Acta Ophthalmologica

View full text Add to dashboard Cite

Purpose: The aim of this study was to describe the clinical ocular surface characteristics in a population-based sample of Finnish elderly people. Methods: This cross-sectional study included 601 subjects (335 females, 266 males) born between the years 1933-1956 and living in Savitaipale, Finland. Ocular surface health was evaluated using a comprehensive set of diagnostic tests. Previous dry eye (DE) diagnosis and history of drug treatment of DE were also recorded. Differences between sexes were estimated with Wilcoxon rank sum test and Fisher's exact test. Results: Overall, 10% and 33% of people displayed signs of DE and ocular surface disease (OSD), respectively, and 30% had been previously diagnosed with DE and 36% used some form of drugs for DE. Men displayed more severe signs of meibomian gland dysfunction, blepharitis and conjunctival redness (p < 0.001), while women had higher scores in corneal staining (p = 0.005) and OSD Index (p < 0.001). Conclusion: Signs of OSD and DE are common among the Finnish elderly population. However, the diagnosis is affected by the diagnostic criteria used and significant differences exist between sexes. Although women were more frequently diagnosed with DE and OSD and experienced more ocular surface irritation, men had more often lid and meibomian glandrelated issues. The current diagnostic criteria of DE pose a risk of misclassifying men, who commonly display less severe symptoms in comparison with women yet exhibit more severe clinical signs associated especially with the lid margin.

show abstract

Section: Discussionmentioning

confidence: 99%

Ocular surface health of the Finnish elderly population

Aapola

Nättinen

Suurkuukka

et al. 2022

Acta Ophthalmologica

View full text Add to dashboard Cite

show abstract

“…В последние годы в лечении больных с синдромом сухого глаза (ССГ) произошло немало позитивных изменений: разработка и практическое использование новых противовоспалительных, иммуносупрессорных, осмопротективных и метаболических препаратов, стимуляторов секреции компонентов слезной пленки, а также внедрение различных методов обтурации слезоотводящих путей и многое другое [1][2][3][4]. Однако наиболее значительный прогресс в рассматриваемой области традиционно связан с разработкой новых препаратов «искусственной слезы», ассортимент которых непрерывно увеличивается [1,[5][6][7].…”

Section: актуальностьunclassified

New Hyaluronic Acid Preparations in the Treatment of Children with Dry Eye Syndrome

2021

View full text Add to dashboard Cite

The aim of the study was to evaluate the effectiveness of the preparations Optinol® Express Moisture (0.21 %) and Optinol® Deep Moisture (0.4 %) in the treatment of children with dry eye syndrome (DES) and to determine the indications for prescribing these drugs for various etiologies and clinical course of the disease.Patients and methods. The study involved 56 children aged 4–17 years with DES, which were divided into 3 groups, depending on its pathogenetic type. The first consisted of 24 children with DES, which developed on the basis of chronic blepharitis, the second — 12 children with neuroparalytic keratitis, and the third — 18 children with chronic uveitis, in whom DES was caused by prolonged instillations of eye drops with benzalkonium chloride. Each group was divided into 2 more equal subgroups, the first of which was prescribed the drug Optinol® Express Moisture, and the second — Optinol® Deep Moisture with a frequency of 4 times a day.Results. In all children, from the very first days of instillation of the studied drugs, a decrease in the severity of subjective signs of DES (OSDI) was noted, as well as a gradual decrease in the degree of xerotic changes in the ocular surface (severity of its staining with vital dyes) and an increase in the stability of the tear film (M.Norn). At the same time, the positive dynamics of the controlled parameters increased with the continuation of therapy, reaching a maximum by the 30th day of treatment. Moreover, the effectiveness of therapy depended on the severity of xerosis of the ocular surface: it was maximal in children with mild, and minimal in children with an extremely severe form of xerosis (with neuroparalytic keratitis). Moreover, the drug Optinol® Express Moisture was more effective in the treatment of children with mild and extremely severe forms of DES, and Optinol® Deep Moisture — with moderate and severe xerosis.Conclusion. The preparations Optinol® Express Moisture and Optinol® Deep Moisturization are effective in the treatment of children with DES, which has developed on the basis of pathology of the ocular surface of neurotrophic and artifact genesis, as well as increased volatility of the precorneal tear film against the background of chronic blepharitis.

show abstract

“…При этом на протяжении уже многих лет основу ме дикаментозного лечения больных с ССГ составляет так на зываемая слезозаместительная терапия, наиболее доступная для практикующих врачей. Она закономерно базируется на инстилляциях препаратов искусственной слезы, число ко торых непрерывно растет, в том числе и в нашей стране, где сегодня зарегистрированы 47 таких препаратов [4]. Они пред ставляют собой водные pаствоpы гидрофильных полимеров (гидроксипропилметилцеллюлоза, поливиниловый спирт, поливинилпиppолидон, натрия гиалуронат, гидроксипропилгуар, хоцлроитина сульфат, полиакриламид, различные варианты карбомеров и многие другие) с включением кон сервантов и неорганических солей для придания препарату требуемых значений рН и осмолярности [3,[5][6][7].…”

unclassified

Combined artificial tear medications in the treatment of patients with dry eye syndrome

Brzhesky

2022

Rossijskij oftalʹmologičeskij žurnal

View full text Add to dashboard Cite

In the treatment of patients with dry eye syndrome, the main measure is tear replacement therapy, the most accessible for practicing physicians. It is understandably based on the instillations of artificial tear medications, whose number is steadily growing. In Russia, there are 47 registered medications of this type. Considering the set of requirements for artificial tear medications (which are expected to moisturize the ocular surface, stop the hyperosmolarity of the tear film, ensure osmo-protection and reduce inflammation in the tissues of the ocular surface, as well as activate their reparative regeneration), the most promising medications are those containing two or more active ingredients. One such medication is Oftolik ® medium-viscosity tear substitute that contains a combination of 1.4 % polyvinyl alcohol and 0.6 % polyvinylpyrrolidone. The moisturizing effect of these polymers is complemented by reparative regeneration stimulation (polyvinyl alcohol) and the production of endogenous interferon (polyvinylpyrrolidone). Multiple studies confirmed high clinical efficacy of the medication for the treatment of patients with the main pathogenetic types of dry eye syndrome, as well as its syndromal and secondary symptomatic forms (computer visual syndrome) and revealed. As these effects are achieved with no significant side effects, we can recommend Oftolik® and its preservative-free form Oftolik BK ® for wide clinical use.

show abstract

TFOS European Ambassador meeting: Unmet needs and future scientific and clinical solutions for ocular surface diseases

Cited by 11 publications

References 23 publications

Ocular surface health of the Finnish elderly population

Ocular surface health of the Finnish elderly population

New Hyaluronic Acid Preparations in the Treatment of Children with Dry Eye Syndrome

Combined artificial tear medications in the treatment of patients with dry eye syndrome

Contact Info

Product

Resources

About